ImmunityBio (IBRX) Net Cash Flow (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Net Cash Flow data on file, last reported at $116.9 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 241.23% year-over-year to $116.9 million in Q1 2026; TTM through Mar 2026 was $145.2 million, a 300.99% increase from a year earlier, with the FY2025 full-year figure at -$54.5 million, up 55.31% from the prior year.
• Net Cash Flow for Q1 2026 stood at $116.9 million, up from $28.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for IBRX reached as high as $134.5 million in Q3 2023 and fell as low as -$144.5 million in Q1 2022.
• Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of $319000.0 in 2022.
• Across the five-year window, Net Cash Flow slumped 1564.0% in 2022 and soared 27334.8% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at $319000.0 in 2022, then surged by 27334.8% to $87.5 million in 2023, then tumbled by 63.87% to $31.6 million in 2024, then fell by 11.05% to $28.1 million in 2025, then soared by 315.56% to $116.9 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $116.9 million in Q1 2026, $28.1 million in Q4 2025, and -$76.7 million in Q3 2025.